Vinblastine sulfate inj
Products billed under this code include Vinblastine Sulfate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Vinblastine Sulfate.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Vinblastine Sulfate | FreseniUS Kabi USA, LLC | 63323-0278-10 | 10 | $57.54 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.754 | +$0.146 | 1 MG | Vinblastine sulfate inj | v1, posted September 17, 2026 |
| 3Q26 | $5.608 | +$0.456 | 1 MG | Vinblastine sulfate inj | v1, posted September 15, 2026 |
| 2Q26 | $5.152 | −$0.031 | 1 MG | Vinblastine sulfate inj | v1, posted September 15, 2026 |
| 1Q26 | $5.183 | −$0.117 | 1 MG | Vinblastine sulfate inj | v1, posted September 15, 2026 |
| 4Q25 | $5.30 | +$0.009 | 1 MG | Vinblastine sulfate inj | v1, posted September 8, 2026 |
| 3Q25 | $5.291 | +$0.155 | 1 MG | Vinblastine sulfate inj | v1, posted March 10, 2026 |
| 2Q25 | $5.136 | +$0.302 | 1 MG | Vinblastine sulfate inj | v1, posted March 10, 2026 |
| 1Q25 | $4.834 | +$0.401 | 1 MG | Vinblastine sulfate inj | v1, posted December 19, 2025 |
| 4Q24 | $4.433 | +$0.553 | 1 MG | Vinblastine sulfate inj | v1, posted June 11, 2025 |
| 3Q24 | $3.88 | −$1.143 | 1 MG | Vinblastine sulfate inj | v1, posted June 11, 2025 |
| 2Q24 | $5.023 | +$0.807 | 1 MG | Vinblastine sulfate inj | v1, posted March 11, 2025 |
| 1Q24 | $4.216 | +$0.145 | 1 MG | Vinblastine sulfate inj | v1, posted December 19, 2024 |
| 4Q23 | $4.071 | +$0.119 | 1 MG | Vinblastine sulfate inj | v1, posted October 10, 2024 |
| 3Q23 | $3.952 | −$0.036 | 1 MG | Vinblastine sulfate inj | v1, posted June 5, 2024 |
| 2Q23 | $3.988 | +$0.055 | 1 MG | Vinblastine sulfate inj | v1, posted February 23, 2024 |
| 1Q23 | $3.933 | +$0.023 | 1 MG | Vinblastine sulfate inj | v1, posted December 6, 2023 |
| 4Q22 | $3.91 | −$0.097 | 1 MG | Vinblastine sulfate inj | v1, posted June 22, 2023 |
| 3Q22 | $4.007 | −$0.01 | 1 MG | Vinblastine sulfate inj | v1, posted June 9, 2023 |
| 2Q22 | $4.017 | +$0.109 | 1 MG | Vinblastine sulfate inj | v1, posted December 14, 2022 |
| 1Q22 | $3.908 | +$0.555 | 1 MG | Vinblastine sulfate inj | v1, posted June 8, 2022 |
| 4Q21 | $3.353 | −$0.72 | 1 MG | Vinblastine sulfate inj | v1, posted June 2, 2022 |
| 3Q21 | $4.073 | +$0.085 | 1 MG | Vinblastine sulfate inj | v1, posted June 2, 2022 |
| 2Q21 | $3.988 | +$0.31 | 1 MG | Vinblastine sulfate inj | v1, posted March 1, 2022 |
| 1Q21 | $3.678 | – | 1 MG | Vinblastine sulfate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.